Energy Vault Closes Acquisition of 850 MW Energy Storage Portfolio from BayWa r.e. AG, Establishing Immediate Operational Platform to Capture Growth in Japan

 WESTLAKE VILLAGE, Calif. - 

Acquisition transfers a premium 850 MW Japanese BESS development portfolio and an experienced local development team from BayWa r.e. AG, one of the world’s leading renewable energy independent power producers

Portfolio includes 350 MW of near term, advanced-stage projects expected to reach NTP in 2H 2027, with COD beginning in mid-2028, plus 500 MW of early-stage projects supporting long-term growth and development

Japanese projects are expected to be designed with three-hour duration, generating higher EBITDA per MW than typical shorter-duration BESS projects in Texas.

Transaction brings Energy Vault’s global owned asset portfolio for near term projects underway to 1.1 GW, contributing to $180M+ in expected annual recurring EBITDA as the projects come online

(BUSINESS WIRE)--Energy Vault Holdings, Inc. (NYSE: NRGV) (“Energy Vault” or the “Company”), a global leader in sustainable grid-scale energy storage and AI compute infrastructure solutions, today announced the successful completion of its previously announced acquisition of an 850 MW Battery Energy Storage System (“BESS”) development portfolio in Japan from BayWa r.e. AG, a leading global renewable energy developer and independent power producer.

The closing of the transaction officially establishes Energy Vault’s operational presence in Japan, one of the most attractive and structurally advantaged energy storage markets among developed economies. The acquisition provides Energy Vault with an immediate in-country platform, a premium project pipeline, and a highly experienced local development team with deep expertise in land rights, regulatory permitting, and utility interconnections — capabilities that are essential to scaling successfully in Japan’s complex and rapidly growing energy storage market.

The team and portfolio were carefully selected and originate from BayWa r.e., one of the world’s most sophisticated renewable energy platforms. For Energy Vault, the strategic value of the acquisition extends beyond megawatts alone: it adds proven local execution capability, accelerates market entry, and positions the Company to build a long-term owned-asset platform in a market with strong demand for flexible, reliable, and dispatchable energy storage.

The acquired portfolio includes approximately 350 MW of advanced-stage BESS projects expected to reach Notice to Proceed (“NTP”) in the second half of 2027, with Commercial Operation Dates (“COD”) expected to begin in mid-2028. An additional 500 MW of early-stage projects provides a multi-year development runway and meaningful expansion potential as Energy Vault scales its Japanese platform. Importantly, the advanced-stage projects are expected to be configured with three hours of storage duration. This provides greater energy capacity per MW than shorter-duration BESS projects more commonly seen in other markets, including the United States, and is expected to enhance the long-term revenue potential and asset value of the portfolio. In addition, Japan’s relatively low cost of financing further strengthens project-level economics, making the market particularly attractive for Energy Vault’s asset ownership strategy.

“This acquisition marks a significant step in Energy Vault’s global growth strategy and establishes our direct operating platform in one of the world’s most compelling energy storage markets,” said Robert Piconi, Chairman and Chief Executive Officer of Energy Vault. “By completing this acquisition, we have secured not only a premium BESS development portfolio, but also an experienced local team from one of the most respected renewable energy platforms globally in BayWa Renewables. Japan’s need for flexible, reliable storage is accelerating, and Energy Vault is well positioned to deliver projects at scale while creating long-term, predictable value for our shareholders.”

“Japan is a strategically important market for energy storage, and we are pleased to have successfully transferred this high-quality portfolio to Energy Vault,” said Daniel Gaefke, Group Chief Operating Officer of BayWa r.e. “This transaction reflects BayWa r.e.’s ability to originate, develop, and monetize premium renewable energy assets globally. With its integrated technology platform, execution capability, and asset ownership strategy, Energy Vault is well positioned to advance these projects and support Japan’s energy transition.”

The formal addition of BayWa r.e.’s Japanese portfolio brings Energy Vault’s global owned asset base — including acquired, under-construction, and operating assets — to more than 1 GW across energy storage and AI compute infrastructure. Once fully constructed and operational, this growing owned-asset portfolio is expected to support more than $180M in anticipated annual recurring EBITDA, reinforcing Energy Vault’s transition toward a capital-efficient, recurring revenue business model.

With the acquisition now closed, Energy Vault intends to continue scaling its Japanese presence by advancing the acquired projects, evaluating additional development opportunities, and deploying storage solutions tailored to Japan’s grid needs, safety requirements, and long-term power market dynamics. The Company will also assess next-generation battery chemistries and customized storage configurations designed to maximize value in Japan’s evolving energy landscape.

About Energy Vault

Energy Vault® develops, deploys and operates utility-scale energy storage solutions designed to transform the world’s approach to sustainable energy storage. The Company’s comprehensive offerings include proprietary battery, gravity and green hydrogen energy storage technologies supporting a variety of customer use cases delivering safe and reliable energy system dispatching and optimization. Each storage solution is supported by the Company’s technology-agnostic energy management system software and integration platform. Unique to the industry, Energy Vault’s innovative technology portfolio delivers customized short, long and multi-day/ultra-long duration energy storage solutions to help utilities, independent power producers, and large industrial energy users significantly reduce levelized energy costs while maintaining power reliability. Since 2024, Energy Vault has executed an “Own & Operate” asset management strategy developed to generate predictable, recurring and high margin tolling revenue streams, positioning the Company for continued growth in the rapidly evolving energy storage asset infrastructure market. Please visit www.energyvault.com for more information.

Forward-Looking Statements

This press release includes forward-looking statements that reflect the Company’s current views with respect to, among other things, the Company’s operations and financial performance. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “contemplate,” “continue,” “suggest,” “plan,” “potential,” “predict,” “believe,” “intend,” “project,” “forecast,” “estimate,” “target,” “project,” “projections,” “should,” “target,” “could,” “would,” “may,” “might,” “will” and other similar expressions. We base these forward-looking statements or projections on our current expectations, plans and assumptions, which we have made in light of our experience in our industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at the time. These forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These forward-looking statements are only predictions based upon our current expectations and projections about future events. These forward-looking statements involve significant risks and uncertainties that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including changes in our strategy, expansion plans, customer opportunities, future operations, future financial position, estimated revenues and losses, expected monetization of tax credits, expected financings, projected costs, prospects and plans; the uncertainly of our awards, bookings, backlog and developed pipeline equating to future revenue; the lack of assurance that non-binding letters of intent and other indications of interest can result in binding financings, orders or sales; the possibility of our products or services to be or alleged to be defective or experience other failures; the implementation, market acceptance and success of our business model and growth strategy; our ability to develop and maintain our brand and reputation; developments and projections relating to our business, our competitors, and industry; the impact of macroeconomic uncertainty, including with respect to uncertainty about the future relationship between the United States and other countries with respect to trade policies and tariffs; changes in tax laws and government regulations and the impact of those changes on us, including as a result of the One Big Beautiful Bill Act and its changes to the Internal Revenue Code of 1986, as amended and the clean-energy tax credits established under the Inflation Reduction Act of 2022; investment in development projects that may not achieve commercial operations in our predicted timeframe or at all; our efforts to diversify our supply chain to lessen the impact of tariffs; the ability of our suppliers to deliver necessary components or raw materials for construction of our energy storage systems in a timely manner; our expectations regarding our ability to obtain and maintain intellectual property protection and not infringe on the rights of others; expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012; our future capital requirements and sources and uses of cash; developments in U.S. and global trade policy; the international nature of our operations and the impact of war or other hostilities on our business and global markets; our ability to obtain funding for our operations and future growth; and our business, expansion plans and opportunities, including our expansion into owned and operated projects; our ability to successfully consummate our proposed acquisition in Japan; and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 18, 2026, as such factors may be updated from time to time in its other filings with the SEC, accessible on the SEC’s website at www.sec.gov. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Any forward-looking statement made by us in this press release speaks only as of the date of this press release and is expressly qualified in its entirety by the cautionary statements included in this press release. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable laws. You should not place undue reliance on our forward-looking statements.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260527219283/en/

Permalink

https://aetoswire.com/en/news/54542676

Contacts

 Energy Vault Contacts:

Investors energyvaultIR@icrinc.com

Media media@energyvault.com

Eskom Media Contact:

Mediadesk@eskom.co.za

 

SLB and Vår Energi Expand Digital Collaboration to Scale Well and Integrated Field Development Planning

 HOUSTON - Thursday, 28. May 2026 AETOSWire 

Agreement supports Vår Energi’s ambition to reduce time to first oil, building on multi-discipline, collaborative well planning workflows that reduce cycle times from months to days

(BUSINESS WIRE)--Global energy technology company SLB (NYSE: SLB) today announced an expanded collaboration with Vår Energi to scale well planning and integrated field development planning across its Norwegian Continental Shelf operations. With collaborative well planning already reducing cycle times from months to days and integrated field development planning expected to support similar benefits, the expanded deployment is designed to support faster, more consistent decision-making as operators work to sustain production from mature offshore assets while managing increasing development complexity.

As part of the expanded collaboration, Vår Energi is deploying the Delfi™ digital platform to connect exploration, subsurface evaluation, well planning, subsea design, field development planning, and production in a cloud-native environment. By enabling teams to work concurrently using shared data and standardized workflows, the approach reduces handoffs and rework and supports more consistent, timely decision-making from early evaluation through development planning.

“As offshore developments become more complex, performance increasingly depends on how quickly teams can align, evaluate options and make decisions using trusted data,” said Rakesh Jaggi, president of SLB’s digital business. “By bringing disciplines together in an integrated digital environment, operators can shorten planning cycles and improve the speed and quality of decisions needed to progress opportunities, including marginal subsea tiebacks.”

The expanded collaboration reflects a broader shift toward cloud-based planning approaches that help operators reduce time between key development milestones, improve coordination across disciplines and maximize value from existing resources in mature basins.

Key Points:

SLB and Vår Energi are scaling digital field development planning on the Delfi™ digital platform across the Norwegian Continental Shelf to improve progression from discovery to development.

Validation reduced planning cycle times from months to weeks, demonstrating measurable impact at scale.

Under the agreement, Vår Energi is deploying the Delfi™ digital platform to connect exploration, subsurface evaluation, well planning, subsea design, field development planning, and production in a cloud-native environment.

Standardized, integrated workflows enable concurrent cross-discipline work, reducing handoffs and rework while improving timely, trusted-data decisions for mature offshore assets, including marginal subsea tiebacks.

About SLB

SLB (NYSE: SLB) is a global technology company that has driven energy innovation for 100 years. With a global footprint in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at slb.com.

Cautionary Statement Regarding Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws — that is, statements about the future, not about past events. Such statements often contain words such as “expect,” “may,” “can,” “estimate,” “intend,” “anticipate,” “will,” “potential,” “projected" and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as forecasts or expectations regarding the deployment of, or anticipated benefits of, SLB’s new technologies and partnerships; statements about goals, plans and projections with respect to sustainability and environmental matters; forecasts or expectations regarding energy transition and global climate change; and improvements in operating procedures and technology. These statements are subject to risks and uncertainties, including, but not limited to, the inability to achieve net-negative carbon emissions goals; the inability to recognize intended benefits of SLB’s strategies, initiatives or partnerships; legislative and regulatory initiatives addressing environmental concerns, including initiatives addressing the impact of global climate change; the timing or receipt of regulatory approvals and permits; and other risks and uncertainties detailed in SLB’s most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. If one or more of these or other risks or uncertainties materialize (or the consequences of such a development changes), or should underlying assumptions prove incorrect, actual outcomes may vary materially from those reflected in our forward-looking statements. The forward-looking statements speak only as of the date of this press release, and SLB disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260528629872/en/

Permalink

https://www.aetoswire.com/en/news/54542982

Contacts

 

Media

Josh Byerly – SVP of Global Communications

Moira Duff – Director of External Communications

SLB

Tel: +1 (713) 375-3407

media@slb.com

Investors

James R. McDonald – SVP of Investor Relations & Industry Affairs

Joy V. Domingo – Director of Investor Relations

SLB

Tel: +1 (713) 375-3535

investor-relations@slb.com

Rubedo’s RLS-1496 Reduces Actinic Keratosis Pre-Cancerous Skin Lesions by 46% at Four Weeks with Minimal Irritation in Preliminary Results of Phase 1b/2a Study

 SAN FRANCISCO - Thursday, 28. May 2026

RLS-1496 is an investigational, first-in-class, disease-modifying, selective glutathione peroxidase 4 (GPX4) modulator that targets pathologic senescent and other stressed, aging cells that drive chronic, age-dependent diseases, such as AK, and represents a novel drug category — Adaptive SenoTherapeutics

In recognition of May as Skin Cancer Awareness Month, Rubedo is calling attention to the myths and facts surrounding AKs — and to the urgent need for a new generation of treatments that are effective without the side-effect burden of today's options

 

 

(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a Phase 1b/2a study of RLS-1496 in patients with actinic keratosis (AK), a common age-related condition resulting in precancerous skin lesions, that is most commonly seen after age 65.1 The open-label multi-center trial, conducted in the United States, assessed the safety, tolerability, and clinical effects of RLS-1496 1% cream in adult patients with AK on the forearms. RLS-1496 is the first selective glutathione peroxidase 4 (GPX4) modulator to be studied in human trials, and the first targeting cellular rejuvenation as a new therapeutic pathway in a novel category called Adaptive SenoTherapeutics. Interim data from the study were presented at the RBC Capital Markets Global Healthcare Conference in New York City on May 19, 2026.

Preliminary RLS-1496 Actinic Keratosis Trial Results

The Phase 1b/2a study of RLS-1496 showed a 46% reduction in AK count compared to 11% for untreated control at 4 weeks in the first 18 of 24 patients evaluated

RLS-1496 was associated with favorable safety, with no serious adverse events (AEs) and no discontinuations due to AEs during the 4-week study

RLS-1496 was well-tolerated, causing minimal local irritation, an area of high unmet need in the standard of care

A Phase 2b dose-ranging AK study for RLS-1496 will begin in Q4

“A 46% reduction in AK lesions at four weeks, achieved with minimal irritation, is exciting since so many patients are hesitant to use current treatments due to redness, peeling, pain, and weeks-long recovery,” said Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, who is also a practicing dermatologist. “AKs are precancerous lesions that lead to squamous cell carcinoma, and patients deserve a therapy that is designed to be both effective and tolerable. We look forward to advancing RLS-1496 for AKs, as well as continuing its development in psoriasis, atopic dermatitis, photo-aging, and other degenerative diseases and conditions associated with the aging process.”

These AK data results follow the preliminary results from Rubedo’s recently completed Phase 1b clinical trial, conducted in the European Union, which assessed the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496. This single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin) met its primary safety endpoint, with RLS-1496 also demonstrating early signs of efficacy, including a remarkable 20% decrease in epidermal thickness in psoriasis patients on therapy compared to a 30% increase with patients on vehicle.2

“The preliminary results from this AK trial, coupled with those from our Phase 1 trial in patients with plaque psoriasis, atopic dermatitis, and skin aging, show continued promise for RLS-1496 as the first GPX4 modulator and a new class of Adaptive SenoTherapeutics,” said Rubedo Chief Scientific Officer and Founder Marco Quarta, PhD. “By clearing damaged senescent cells and restoring the health of stressed but viable cells, we aim to address biological aging at its cellular root, with implications that extend well beyond dermatology to fibrosis, metabolic disease, sarcopenia, and neurodegeneration. What makes RLS-1496 particularly exciting is that it appears to act across several fundamental hallmarks of aging — from cellular senescence to autophagy and oxidative stress imbalance. This is the kind of multi-axis biology we believe will define the next generation of true longevity medicines.”

The data from Rubedo’s RLS-1496 AK trial, as well as data from the Phase 1b trial, including a comprehensive data set of 70 subjects assessing RLS-1496 in aging skin, are being compiled for submission to major medical journals and medical meetings.

Actinic Keratosis: A Common Health Condition with an Unmet Need

It is estimated that 58 million Americans have one or more AKs.3 The U.S. annual market size for AKs was $3.55 billion in 2025, and will grow to $4.8 billion by 2035.4 In recognition of Skin Cancer Awareness Month, Rubedo is calling attention to common myths that are believed about AKs and highlighting why new treatments are still urgently needed for the millions of people affected by AKs.

Myth 1: AKs are harmless sun spots and usually go away on their own.

The Facts:

AKs form as a result of long-term sun exposure, and often appear as small, rough patches of skin that can vary in color. They typically are found on sun-exposed areas of the body, including the face, scalp, neck, arms, and hands.3

Left untreated, AKs can progress into squamous cell carcinoma (SCC), which is the second most common skin cancer.5 An estimated 1.8 million cases of SCC are diagnosed each year,6 and it is estimated that 82% of SCCs begin as AKs.5

Myth 2: AKs are rare.

The Facts:

AKs are among the most common diagnoses made by dermatologists, with a global prevalence of approximately 14%.7 The prevalence of AK increases with age, frequently developing after age 50 but most commonly seen after age 65.1

While a single lesion carries a relatively low risk of progression, the presence of one AK indicates a higher likelihood of developing additional lesions over time, increasing the cumulative risk of skin cancer.3

Myth 3: Current AK treatments are good enough.

The Facts:

Available treatments — including topical creams, cryosurgery, and photodynamic therapy — can be effective but are often associated with pain, redness, swelling, crusting, or peeling that can take weeks to heal.8

These side effects lead some patients to delay or discontinue treatment, leaving lesions untreated and increasing the risk that AKs progress to skin cancer.8 New effective treatment approaches with improved tolerability are needed to protect patients from preventable cancer.

About RLS-1496 and GPX4 Modulation

Rubedo’s lead candidate RLS-1496, being developed for topical and oral administration, is a first-in-class, disease-modifying GPX4 modulator selectively targeting pathologic senescent and other stressed, aging cells that drive chronic, age-dependent diseases. These include immunology and inflammation (I&I), dermatology and skin aging, metabolic syndrome (obesity, diabetes, liver fibrosis), sarcopenia, and neurodegenerative disease.

In certain pathologic cells, aging is associated with an imbalance in GPX4. Modulation of GPX4 sensitizes cells to ferroptosis, which is a type of programmed cell death and is believed to be an Achilles heel of senescent cells. By modulating GPX4 in ferroptosis-sensitive senescent “aged” cells, RLS-1496 may be able to clear these cells to fight disease and also support healthy cells to function properly and restore tissue homeostasis. Beyond its targeted senolytic function in triggering selective ferroptosis within pathological senescent cells, RLS-1496 could also act as a restorative modulator that induces a vital 'redox-reset' through a controlled hormetic response in stressed neighboring cells, effectively clearing the source of chronic inflammation while actively re-establishing healthy tissue homeostasis. This dual-action mechanism represents a novel drug category—Adaptive SenoTherapeutics.

RLS-1496 uses Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™, which identifies targets within pathologic senescent cells and develops selective cellular rejuvenation medicines for these targets.

About Rubedo Life Sciences

Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Our lead drug candidate – RLS-1496, a potential first-in-class disease-modifying GPX4 modulator – is currently in Phase I clinical trials. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Mountain View, CA, USA, and has offices in Milan, Italy. For additional information, visit www.rubedolife.com.

1 Flohil SC, van der Leest RJT, Dowlatshahi EA, et al. Prevalence of Actinic Keratosis and Its Risk Factors in the General Population: The Rotterdam Study. Journal of Investigative Dermatology, Volume 133, Issue 8, 2013, Pages 1971-1978, https://doi.org/10.1038/jid.2013.134

2 Vitari A, Laslavic A, Spellman M, et al. Abstract 0510: Clinical study of RLS-1496 topical cream: Targeting cellular senescence in patients with mild-to-moderate plaque psoriasis. Presented at 2026 Annual Meeting of the Society for Investigative Dermatology (SID). https://www.sidnet.org/wp-content/uploads/2026/05/SID_Chcago26_Abstract_FInal_4.pdf#page=132

3 The Skin Cancer Foundation. Actinic Keratosis Overview. Accessed May 2026. https://www.skincancer.org/skin-cancer-information/actinic-keratosis/

4 Nova1Advisor. U.S. Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical/Drugs, Surgery, Photodynamic Therapy), By Drug Class, By Product, By End-use, And Segment) - Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2026-2035. Accessed May 2026. https://www.novaoneadvisor.com/report/us-actinic-keratosis-treatment-market

5 Li Z, Lu F, Zhou F, et al. (2025). From actinic keratosis to cutaneous squamous cell carcinoma: the key pathogenesis and treatments. Frontiers in immunology, 16, 1518633. https://doi.org/10.3389/fimmu.2025.1518633

6 The Skin Cancer Foundation. Squamous Cell Carcinoma Overview. Accessed May 2026. https://www.skincancer.org/skin-cancer-information/squamous-cell-carcinoma/

7 George CD, Lee T, Hollestein LM, et al. Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis, British Journal of Dermatology, Volume 190, Issue 4, April 2024, Pages 465–476, https://doi.org/10.1093/bjd/ljad371

8 Balcere A, Rone Kupfere M, Čēma I, Krūmiņa A. (2019). Prevalence, Discontinuation Rate, and Risk Factors for Severe Local Site Reactions with Topical Field Treatment Options for Actinic Keratosis of the Face and Scalp. Medicina (Kaunas, Lithuania), 55(4), 92. https://doi.org/10.3390/medicina55040092

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260528143952/en/

Permalink

https://www.aetoswire.com/en/news/54543296

Contacts

 

Investor Contact:

Rubedo Chief Business Officer Ali Siam

alisiam@rubedolife.com

781-974-9559

Media Contact:

Peter Collins

p.collins@togorun.com

908-499-1200

 

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026

 TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEA

Oral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1%

(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago. The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA).

Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, senior author of the NEJM manuscript and first author of the ASCO abstract, said:

“Results from the HERIZON-GEA-01 published in The New England Journal of Medicine and presented in an oral presentation at ASCO provide new data about the regimen of tislelizumab added to zanidatamab plus chemotherapy, which demonstrated meaningfully improved outcomes for patients with HER2-positive gastroesophageal adenocarcinoma. In particular, the findings show that this regimen resulted in a survival benefit, even in patients with PD-L1 <1%. This combination has the potential to be an important new treatment option in areas of high unmet need in HER2+ GEA.”

Key findings published in The New England Journal of Medicine

Overall survival (OS): A statistically significant and clinically meaningful improvement in OS with ZIIHERA plus TEVIMBRA and chemotherapy, reaching a median OS of 26.4 months; mOS of 24.4 months was reported with ZIIHERA plus chemotherapy, and 19.2 months with the control arm.

Progression-free survival (PFS): A statistically significant and clinically meaningful improvement in PFS in both ZIIHERA-containing arms with a median PFS of 12.4 months.

Duration of Response (DoR): Median DoR of 20.7 months with ZIIHERA and TEVIMBRA plus chemotherapy; median DoR of 14.3 months with ZIIHERA plus chemotherapy and 8.3 months with the control arm.

Dr. Geoffrey Ku, Associate Attending physician on the Gastrointestinal Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center, author of the NEJM manuscript and the ASCO abstract, said:

“This practice-changing study demonstrates that zanidatamab is clearly superior to trastuzumab, with a manageable safety profile, in HER2-positive GEA. Moreover, the addition of tislelizumab contributes to the prolongation of overall survival and remarkable durability of responses, with benefit in both PD-L1 positive and negative tumors. If approved, the combination of zanidatamab, tislelizumab and chemotherapy should become the standard of care in untreated metastatic or locally advanced HER2-positive GEA patients irrespective of the tumor PD-L1 status.”

Oral presentation with new data at ASCO 2026 demonstrates benefit regardless of PD-L1 status

With 26 months of follow-up, ZIIHERA plus TEVIMBRA and chemotherapy meaningfully improved PFS and OS were observed in both PD-L1-positive and PD-L1-negative patients compared with the control arm; data were consistent between tumor area positivity (TAP) and combined positive score (CPS).

In PD-L1 TAP <1% and ≥1% patients, the 18-month PFS was 50.3% and 42.6%, respectively, and the 24-month OS was 63.7% and 53.5% with ZIIHERA plus TEVIMBRA and chemotherapy.

In PD-L1-negative patients (TAP <1%), median OS was 29.7 months with ZIIHERA plus TEVIMBRA and chemotherapy compared with 15.8 months with the control arm. In PD-L1-positive patients (TAP≥1%), median OS was 26.4 months with ZIIHERA plus TEVIMBRA and chemotherapy compared with 21.2 months in the control arm. Findings were consistent across PD-L1 assessment methods.

In TAP<1%, the ZIIHERA plus TEVIMBRA and chemotherapy regimen resulted in a mPFS of 18.5 months compared with mPFS of 7.9 months in the control arm, while in TAP≥1% patients, the mPFS was 11.3 months vs. mPFS of 8.3 months in the control arm

Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne Medicines, said:

“The HERIZON-GEA-01 results – now published in The New England Journal of Medicine with a detailed sub-group analysis presented in an oral session at ASCO – strengthen the evidence supporting the role of TEVIMBRA in driving a sustained and statistically significant overall survival benefit. With a median OS of more than 26 months, unprecedented in this disease, the TEVIMBRA-containing arm is positioned as a compelling new therapeutic approach in a disease where there remains a critical unmet need.”

The safety findings for the ZIIHERA plus TEVIMBRA and chemotherapy arm were generally consistent with the known effects of HER2-directed therapy and immunotherapy, and no new safety signals were identified. Diarrhea was the most common Grade ≥3 treatment-related adverse event (TRAE) in 24.5% of patients with ZIIHERA plus TEVIMBRA and chemotherapy, 20.0% of patients in the ZIIHERA plus chemotherapy arm, and 12.9% in the trastuzumab plus chemotherapy arm, noting that the median treatment duration was longest for the triplet arm at 43.1 weeks (vs. 31.0 weeks with ZIIHERA plus chemotherapy and 30.0 weeks in the control arm). A mandatory anti-diarrheal prophylaxis was established during the first cycle, and discontinuation rates due to drug-related diarrhea were relatively low at 4.1%, 1.3%, and 0% of patients, respectively, with most diarrhea events occurring early in the trial.

Regulatory Status

The U.S. FDA has accepted a supplemental Biologics License Applications (sBLA) for TEVIMBRA and has granted it priority review. In addition, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted sBLAs for ZIIHERA and for TEVIMBRA for the first-line treatment of advanced/metastatic HER2+ GEA. BeOne holds the rights to ZIIHERA in Asia (excluding India and Japan), Australia, and New Zealand, and intends to work with authorities in these markets to expedite regulatory submissions.

About the HERIZON-GEA-01 Phase 3 Trial

HERIZON-GEA-01 (NCT05152147) is a global, randomized, open-label Phase 3 trial, conducted jointly with Jazz Pharmaceuticals, to evaluate and compare the efficacy and safety of ZIIHERA plus chemotherapy, with and without TEVIMBRA, to the standard of care (trastuzumab plus chemotherapy) as first-line treatment for adult patients with advanced/metastatic HER2+ GEA. The trial randomized 914 patients from approximately 300 trial sites in more than 30 countries. Patients for this trial had unresectable locally advanced, recurrent or metastatic HER2+ GEA (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Patients were randomized to the three trial arms: ZIIHERA in combination with chemotherapy and TEVIMBRA; ZIIHERA in combination with chemotherapy; and trastuzumab plus chemotherapy. The trial is evaluating dual primary endpoints, PFS per blinded independent central review (BICR) and OS.

About Gastroesophageal Adenocarcinoma

Gastroesophageal adenocarcinoma (GEA), which includes cancers of the stomach, gastroesophageal junction, and esophagus, is the fifth most common cancer worldwide. Approximately 20% of GEA patients have HER2-positive disease.1,2,3, which has high morbidity and mortality, and patients are urgently in need of new treatment options. The overall prognosis for patients with GEA remains poor, with a global five-year survival rate of less than 30% for gastric cancer and about 19% for GEA.4

About ZIIHERA (zanidatamab)

ZIIHERA (zanidatamab) is a bispecific human epidermal growth factor receptor 2, or HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.5

Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is approved in China for the treatment of patients who have unresectable, locally advanced, or metastatic HER2-high expression (IHC 3+) biliary tract cancer (BTC) and who have received prior systemic therapy. ZIIHERA has also been granted accelerated approval in the U.S. and conditional marketing authorization in the European Union for eligible BTC patients. Zanidatamab is being developed by Jazz and BeOne under license agreements from Zymeworks, which first developed the molecule. BeOne has licensed zanidatamab from Zymeworks in Asia (excluding India and Japan), Australia and New Zealand. Jazz Pharmaceuticals has rights in all other regions.

ZIIHERA is a registered trademark of Zymeworks BC Inc.

About TEVIMBRA (tislelizumab)

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.

TEVIMBRA is the foundational asset of BeOne’s solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 15,000 patients enrolled to date in 30+ countries and regions across 71 trials, including 21 registration-enabling studies. TEVIMBRA is approved in over 50 countries, and more than 2 million patients have been treated globally.

Select Important Safety Information

Serious and sometimes fatal adverse reactions occurred with TEVIMBRA treatment. Warnings and precautions include severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic adverse reactions, nephritis with renal dysfunction, and solid organ transplant rejection. Other warnings and precautions include infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.

Please see full U.S. Prescribing Information including the U.S. Medication Guide.

The information in this press release is intended for a global audience. Product indications vary by region.

About BeOne

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential benefits of ZIIHERA and TEVIMBRA; the potential of TEVIMBRA plus ZIIHERA and chemotherapy to become an important new treatment option; BeOne’s plans to work with authorities in certain markets to expedite regulatory submissions; BeOne’s expectations regarding ZIIHERA’s and TEVIMBRA’s clinical development and regulatory milestones; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

To access BeOne media resources, please visit our Newsroom site.

   

1 Abrahao-Machado I.F., et al. HER2 testing in gastric cancer: An update WorldJGastroenterol. 2016;22(19):4619-4625.

2 Van Custem E., et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-484.

3 Stroes, C.I., et al. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. CancerTreatRev. 2021;99:102249.

4 Battaglin F, et al. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell International. 2018;18(99).

5 ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.).

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260527389623/en/

Permalink

https://www.aetoswire.com/en/news/54542900

Contacts

 

Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com

Media Contact

Kyle Blankenship

+1 667-351-5176

media@beonemed.com

 

IHS Towers Publishes 2025 Sustainability Report

LONDON - Tuesday, 26. May 2026 

(BUSINESS WIRE)--IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report.

The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders.

IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity.

In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report.

Sam Darwish, Chairman & CEO, IHS Towers, commented, “At IHS Towers, we remain committed to advancing digital inclusion and delivering meaningful impact through our four sustainability pillars. We believe mobile connectivity has the power to unlock significant social value, and we recognize the critical role it plays in expanding access to education and economic opportunity.

Our 2025 Sustainability Report highlights this impact, showcasing our community‑focused initiatives across Africa and Latin America. We are proud of the long‑term value we continue to create for our stakeholders and are pleased to share the progress we are making across key HSSE priorities, our Carbon Reduction Roadmap, and the $45 million we have invested in our communities since 2017.”

2025 Sustainability Report Highlights

As of and for the year ended December 31, 2025, we reported environmental, social and governance (“ESG”) related progress including:

Environment

    Carbon Reduction Roadmap:
        Reduced our Scope 1 and Scope 2 kilowatt-hour emissions intensity by approximately 21.4%, compared with our 2021 baseline emissions data1
    Commenced the planting of over 25,000 seedlings across nine hectares in Brazil’s Amazon region in collaboration with the Institute of Conservation and Sustainable Development of the Amazon (Idesam)
    Partnered with the Federal Capital Territory Administration in Nigeria to promote the adoption of clean cooking gas through the 'Project Breathe Clean Air-Abuja’ and provide 5,000 households with LPG cylinders and cookers
    Continued an initiative in Nigeria to install solar-powered streetlights, donating 700 units of streetlights across communities nationwide
    Launched a pilot project with ApiFusion at two rural tower sites to promote sustainable beekeeping and community empowerment

Social

    Reported no recordable work-related injuries or fatalities among IHS employees
    29% of our employees were female, an increase from 27% in 2024, and 71% were male
    Employees completed 13 hours of training on average on the IHS Academy
    Spent $8.2 million on community-focused sustainability initiatives, bringing the total investment in our local communities to $45 million since 2017
    Enhanced digital inclusion by:
        Training more than 140,000 students in digital skills through Nigeria’s 3 Million Technical Talent (3MTT) initiative
        Reaching 100,000 children through a literacy program in Côte d’Ivoire
        Training over 9,500 students in STEM skills in Brazil, Nigeria, South Africa and Zambia

Governance

    IHS South Africa achieved a Level 1 rating in its Broad-Based Black Economic Empowerment (B-BBEE) audit
    Maintained our ISO 37001 Anti-Bribery Management System certification2
    Scored 37 (out of 100) in the 2025 S&P Global Corporate Sustainability Assessment (CSA Score)3
    Continued driving high standards of integrity throughout our supply chain; 7,861 supplier employees completed training in topics relating to our Supplier Code of Conduct
    98% of employees, versus 96% in 2024, completed annual Anti-Bribery and Corruption training

For more information, please visit www.ihstowers.com/sustainability

About IHS Towers: IHS Towers is one of the largest independent owners, operators and developers of shared communications infrastructure in the world by tower count and is solely focused on the emerging markets. The Company has over 37,000 towers across its seven markets, including Brazil, Cameroon, Colombia, Côte d’Ivoire, Nigeria, South Africa and Zambia. For more information, please email: communications@ihstowers.com or visit: www.ihstowers.com

Cautionary statements

This press release contains forward-looking statements. We intend such forward-looking statements to be covered by relevant safe harbor provisions for forward-looking statements (or their equivalent) of any applicable jurisdiction, including those contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this press release may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “commits,” “projects,” “contemplates," “believes,” “estimates,” “forecast,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this press release include, but are not limited to statements regarding our business strategy, plans, market growth and our objectives our sustainability program and Carbon Reduction Roadmap.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to general macroeconomic conditions in the countries in which we operate; our inability to successfully execute our business strategy and operating plans, or deliver on our sustainability or environmental, social and governance (ESG) strategy and initiatives under anticipated costs, timelines, and complexity, such as our Carbon Reduction Roadmap (Project Green); environmental liability; and the important factors discussed in the section titled “Risk Factors” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2025.

The forward-looking statements in this press release are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. You should read this press release and the documents that we reference in this press release with the understanding that our actual future results, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Additionally, we may provide information herein that is not necessarily “material” under the federal securities laws for SEC reporting purposes, but that is informed by various ESG standards and frameworks (including standards for the measurement of underlying data), and the interests of various stakeholders. Much of this information is subject to assumptions, estimates or third-party information that is still evolving and subject to change. For example, our disclosures based on any standards may change due to revisions in framework requirements, availability of information, changes in our business or applicable government policies, or other factors, some of which may be beyond our control. These forward-looking statements speak only as of the date of this press release. Except as required by applicable law, we do not assume, and expressly disclaim, any obligation to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events or otherwise. Additionally, the information included in our 2025 Sustainability Report, including highlights provided in this press release, are subject to certain important disclaimers that should be read and considered in concert with such information.

1 Scope 1 and Scope 2 emissions and emissions intensity for 2021 have been recalculated to account for IHS Towers’ sale of IHS Kuwait in 2024.

2 ISO 37001 Anti-Bribery Management System certification has been achieved in the UAE, UK and operating markets.

3 As of December 18, 2025.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260526896179/en/

Permalink
https://www.aetoswire.com/en/news/54541671

Contacts
 

Enquiry: Investor
Contact Info:
IHS Towers
1 Cathedral Piazza
123 Victoria Street
London, SW1E 5BP
United Kingdom
investorrelations@ihstowers.com

Enquiry: Journalist
Contact Info:
Teneo
The Carter Building
11 Pilgram Street
London, EC4V 6RN
United Kingdom
ihstowers@teneo.com

Enquiry: Other
Contact Info:
IHS Towers
1 Cathedral Piazza
123 Victoria Street
London, SW1E 5BP
United Kingdom
+442081061600
communications@ihstowers.com

Kinaxis Convenes Global Supply Chain Leaders at Kinexions North America to Advance Agentic AI and Decision Orchestration

OTTAWA, Ontario - Thursday, 28. May 2026

Annual conference brings customers, partners, and industry leaders together to explore how enterprises are turning decisions into coordinated action

(BUSINESS WIRE)--Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, is set to host Kinexions North America kicking off next week from June 1-3 at The Cosmopolitan of Las Vegas. The company’s flagship conference will bring together global supply chain, business and technology leaders for three days of product innovation, customer insights, and peer networking as Kinaxis continues to advance its focus on AI-driven decision making across the supply chain industry.

This year’s event will spotlight how organizations are applying agentic AI and orchestration, moving beyond insight to execution, and increasingly from decisions to coordinated action. Speakers from global organizations including Merck, Bristol Myers Squibb, Unilever, British American Tobacco, Qualcomm, ExxonMobil, The Hershey Company, Scotts Miracle-Gro, and Veolia, will join Kinaxis executives to share how they are navigating disruption and improving operational outcomes.

Kinaxis CEO, Razat Gaurav is set to deliver his first Kinexions keynote alongside Chief Product Officer, Andrew Bell and Chief of Agentic Solutions, Manik Sharma who will outline the company’s latest advancements in agentic capabilities and the continued evolution of the Maestro™ platform and ecosystem.

Key themes of the conference include:

Agentic AI in practice: How Maestro Agents support decision-making across planning and execution, enabling teams to act with speed while maintaining control

End-to-end orchestration: Connecting decisions across functions, partners, and time horizons to reduce latency and improve alignment

From insight to coordinated action: Customer-led sessions demonstrating how global organizations are turning real-time visibility into measurable operational outcomes

Those unable to attend in person can experience the opening keynote in real time as it is livestreamed globally on June 2 via LinkedIn Live.

“Supply chains don’t struggle because of a lack of data; they struggle because decisions are disconnected,” said Razat Gaurav, CEO of Kinaxis. “What’s changing is that AI is no longer just informing decisions; it’s becoming part of how decisions are made and executed. That requires a way to bring people, data, and AI together so decisions can be aligned and acted on in an orchestrated way across operations. As organizations introduce agentic AI, there is an opportunity for us to transform our ways of working and create a shift from reacting to change to operating with intelligence and continuously adapting as conditions evolve. I'm looking forward to diving deeper into this topic at Kinexions.”

The event will also feature keynote perspectives from Peter Hinssen, a bestselling author and expert on leading through constant disruption, and Michelle Mace Curran, former U.S. Air Force Thunderbird pilot, who will share lessons on decision-making under pressure. Their sessions will complement a broader agenda of customer discussions, expert panels, and product deep dives focused on how supply chain leaders are building more adaptable operations.

Kinexions is supported by partners including Genpact, Accenture, EY, Scott Sheldon, 4flow, Bristlecone, Deloitte, Google Cloud, PlanetTogether, Microsoft, PwC, and Workday and will feature networking experiences and live programming throughout the event, including a performance by globally renowned DJ and music icon Steve Aoki.

Supply chain leaders face persistent disruption, fragmented data, and pressure to act quickly without sacrificing accuracy or accountability. While many have invested in AI, most have yet to operationalize it across the workflows that determine how supply chains respond to change or trust it to drive coordinated, governed action. Kinexions offers a front-row seat to the future where AI, orchestration and execution converge to deliver real outcomes that matter.

Learn more and follow the action: https://www.kinexions.com

Register for the livestreamed keynote: HERE

About Kinaxis

Kinaxis is a leader in modern supply chain planning and orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Source: Kinaxis Inc.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260528255651/en/

Permalink

https://www.aetoswire.com/en/news/54543292

Contacts

 

Media Relations

Erin Boyle | Kinaxis

eboyle@kinaxis.com

+1 519-574-4065

Investor Relations

Rick Wadsworth | Kinaxis

rwadsworth@kinaxis.com

613-907-7613

Visa Expands Commercial Solutions Hub with Integration of Visa Accounts Receivable Manager

 New integration allows issuers to send virtual card details to suppliers, helping automate virtual card adoption for suppliers at scale

(BUSINESS WIRE)--Visa Inc. (NYSE: V), a global leader in digital payments, today announced an expansion of the Visa Commercial Solutions Hub (VCS Hub), further strengthening how issuers and suppliers connect to scale virtual card programs. Through a new integration with Visa Accounts Receivable Manager (Visa AR Manager), eligible issuers gain built-in access to end-to-end processing designed to reduce operational friction and accelerate commercial card growth.

Virtual cards are among the fastest-growing payment methods in commercial payments yet scaling them remains complex. Issuers often face fragmented supplier connectivity, while suppliers are left with manual reconciliation and inconsistent payment flows. By bringing issuer and supplier networks together, by embedding access to Visa AR Manager in the VCS Hub, Visa is helping to simplify these connections and enable more automated, seamless payment experiences across the ecosystem.

Powering issuer growth through a unified commercial payments platform

Launched in 2025, VCS Hub is a globally available platform designed to help issuers support multiple commercial payment use cases through a single, scalable integration. By unifying Visa’s network capabilities, VCS Hub enables issuers to reduce technical complexity, accelerate time to market, and scale virtual card programs more efficiently across their commercial client portfolios.

“Issuers see strong demand for commercial card solutions, but scaling those programs can be unnecessarily complex,” said Gloria Colgan, SVP, Global Product, Commercial Solutions, Visa. “Visa Commercial Solutions Hub reduces that friction, making it easier to connect with suppliers, deliver new capabilities faster, and drive meaningful growth in commercial payments.”

Driving automation and unlocking scale

Now available in 69 geographies, Visa AR Manager, powered by proprietary AI capabilities, addresses key operational barriers that have historically limited virtual card adoption. Through this integration, issuers can send virtual card payments on behalf of their corporate buyers through Visa AR Manager. Visa AR Manager then provides a virtual card automation service to suppliers that reduces manual intervention, can accelerate reconciliation, potentially improving working capital outcomes for suppliers.

Early adopters of Visa AR Manager are already seeing measurable impact, including efficiency gains through increased automation. One customer reported an 89% reduction in days sales outstanding, realized a 300-basis-point net benefit, and enabled fully automated virtual card processing in under two weeks of implementation.

“Visa Accounts Receivable Manager brings true end-to-end automation to commercial payments,” said Abhishek, Global Head of B2B Acceptance, Visa. “By streamlining how payment and invoice data move between issuers and suppliers, we’re helping unlock the full growth potential of virtual card programs.”

Availability

The integrated capability for issuers is expected to launch in September 2026 and will be available at no additional cost to eligible VCS Hub clients, subject to applicable terms and geographic availability. *

Frequently Asked Questions (FAQ)

What is Visa Commercial Solutions Hub (VCS Hub)?

Visa Commercial Solutions Hub is a globally available, unified platform that enables issuers to access Visa and partner capabilities through a single integration. The VCS Hub provides access to a growing range of Visa capabilities and partner solutions, simplifying the deployment and scaling of commercial card programs.

What is Visa Accounts Receivable Manager (Visa AR Manager)?

Visa AR Manager allows issuers to send virtual card details on behalf of their corporate buyer to suppliers enrolled in the Visa AR Manager service. For enrolled suppliers, Visa AR Manager automates accounts receivable processes by streamlining the exchange of payment, remittance, and invoice data. It is designed to reduce manual reconciliation and improve payment efficiency.

What is new in this announcement?

Visa is integrating the Visa AR Manager service for issuers directly into VCS Hub. This gives eligible issuers built-in access to end-to-end virtual card processing and reconciliation capabilities through a single platform.

How does this benefit issuers?

Issuers can reduce technical complexity, accelerate time to market, and scale virtual card programs more efficiently. The integration may also help improve supplier enablement and overall program performance.

How does this benefit suppliers?

Suppliers can gain more consistent, automated payment and reconciliation processes. This can reduce manual work, improve cash flow visibility, and shorten payment cycles.

How does the integration improve virtual card adoption?

By simplifying supplier connectivity and automating payment and reconciliation workflows, the integration reduces key operational barriers that have historically limited virtual card adoption at scale.

What role does AI play in Visa AR Manager?

Visa AR Manager uses proprietary AI capabilities to help match payments with invoices, streamline reconciliation, and reduce exceptions, improving overall processing efficiency.

Where is Visa AR Manager integration with the VCS Hub available?

Visa AR Manager integration will be available in 69 areas globally where Visa AR Manager is currently available.

When will the integrated capability be available?

The integrated VCS Hub and Visa AR Manager capability for issuers is expected to launch in September 2026, subject to geographic readiness.

Who is eligible to access this capability?

The integration will be available at no additional cost to eligible existing VCS Hub issuer clients. Availability for other clients will depend on commercial arrangements and jurisdictional conditions.

What results have Visa AR Manager early adopters seen?

Early adopters have reported significant efficiency gains, including up to an 89% reduction in days sales outstanding, measurable financial benefits, and the ability to enable fully automated virtual card processing within weeks.

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

* Eligible issuers must agree to the VCS Hub Terms of Use, the VCS Hub Product Specific Terms for Visa AR Manager, and additional terms based on access channel to the VCS Hub: B2B Payables terms (if batch file or online), Embedded Payments terms (if embedded in ERP), or applicable Visa Developer Platform/VDP terms (if API). Please contact your Visa representative for more information.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260527308928/en/

Permalink

https://www.aetoswire.com/en/news/54542291

Contacts

 

Media Contact

Brooke Maggiotto - Brooke.maggiotto@visa.com